The FDA issued an RFI seeking venture capital input on a new contract model to connect portfolio companies directly with ...

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...

Detailed price information for Netramark Holdings Inc (AIAI-CN) from The Globe and Mail including charting and trades.

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates ...

Bioassay variability can pose significant challenges due to laboratory conditions, instrumentation, analytical software, cell culture performance and reagent sourcing. These inconsistencies can impact ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...

The FDA has released a plan to stop or reduce the use of primates for testing the safety of certain monoclonal antibodies (mAbs), the latest expansion of the regulator’s efforts to eliminate animal ...

New World Health Organization guidelines for GLP-1 weight-loss drugs state that “intensive behavioral therapy” should be combined with these revolutionizing medications for obesity treatment. In the ...

Objective: To develop and validate a method for therapeutic drug monitoring (TDM) of pyrotinib in human plasma using two-dimensional liquid chromatography (2D-LC) system. Method: The plasma samples ...

Two obesity drugs are among the six new medications that could get faster FDA review under a new pilot program open to products addressing certain national health priorities. Rare and infectious ...